For stubborn melasma flaring during midlife, the clinical gold standard remains Kligman’s Formula or its variants, often referred to as Triple Combination Cream (TCC). This prescription-only formulation typically contains 4% hydroquinone, 0.05% tretinoin, and 0.01% fluocinolone acetonide. Hydroquinone inhibits the enzyme tyrosinase to prevent new melanin formation, while tretinoin increases epidermal turnover to shed existing pigment, and the corticosteroid suppresses the inflammatory response that often exacerbates hyperpigmentation [1]. In Australia, these are frequently compounded to suit individual skin sensitivities and hormonal profiles associated with the perimenopausal transition.
When topical therapies prove insufficient, oral tranexamic acid (TXA) has emerged as a revolutionary adjunct treatment for resistant cases. At low dosages (250mg twice daily), TXA inhibits plasminogen activation, which in turn reduces the melanocyte-stimulating mediators induced by both UV exposure and hormonal fluctuations [2]. This systemic approach is particularly effective for the 'vascular' component of melasma, which often presents as persistent redness alongside brown patches. However, it requires strict medical supervision due to contraindications related to clotting risks [3].
Finally, procedural interventions such as low-fluence Q-switched Nd:YAG lasers or Picosecond lasers can be integrated, though they must be approached with caution to avoid post-inflammatory hyperpigmentation (PIH). For midlife skin, which may have a compromised barrier, these lasers work by photomechanically shattering pigment particles without generating excessive heat [4]. Regardless of the chosen intervention, the 'best' treatment is incomplete without daily application of a high-protection, tinted broad-spectrum sunscreen containing iron oxides, which provides the necessary defence against visible light—a known trigger for midlife pigment flares [5].
Melasma is a complex, chronic disorder of hypermelanosis characterised by symmetrical brown macules, primarily on the face. Its pathogenesis involves a sophisticated interplay between genetic predisposition, ultraviolet (UV) radiation, and hormonal influences. In midlife, the fluctuation of oestrogen and progesterone levels during perimenopause and menopause can sensitise melanocytes, making them hyper-reactive to even minimal environmental triggers [1]. This is further complicated by the 'vascular theory' of melasma, where increased expression of vascular endothelial growth factor (VEGF) leads to an enlarged underlying capillary network that feeds melanocyte activity [2].
Recent research has also highlighted the role of the dermal microenvironment, including the senescence of dermal fibroblasts and the breakdown of the basement membrane. As skin ages, it loses its ability to compartmentalise melanin, allowing pigment to drop into the dermis where it becomes significantly more difficult to treat topically. Understanding these cellular mechanisms is crucial for Australian clinicians when choosing between superficial epidermal treatments and deeper, systemic or light-based therapies that address the vascular and dermal components of the condition [4].
While clinical interventions are often necessary for managing midlife melasma, maintaining the skin’s luminosity and resilience during treatment is equally vital. For those looking for a brightening support system, our [C-Veil Citrine Tonic](https://auremeskin.com.au/products/c-veil-citrine-tonic) includes Ascorbic Acid and Niacinamide to target uneven tone, while the [Cellular Thread](https://auremeskin.com.au/products/cellular-thread) peptide serum features Licorice Root and Bearberry, botanical extracts traditionally recognised for their ability to complement a more uniform, youth-preserved complexion.
FAQ
Why does melasma often worsen or reappear during perimenopause?
Melasma is highly hormone-sensitive; specifically, oestrogen and progesterone receptors are overexpressed in melasmic skin. During perimenopause, the dramatic fluctuations and eventual decline in these hormones can trigger melanocytes to overproduce pigment. Furthermore, midlife skin often exhibits increased 'inflammageing' and a weakened barrier, making it more susceptible to UV-induced damage and visible light, both of which exacerbate hormonal pigmentation [1, 6].
Do I really need a 'tinted' sunscreen for melasma?
Yes, for melasma patients, tinted sunscreens are superior to untinted versions. The iron oxides used to create the tint provide a physical barrier against high-energy visible light (HEVL) or 'blue light'. Studies have shown that visible light can induce more persistent and intense hyperpigmentation in darker skin phototypes than UV radiation alone. In the Australian climate, this extra layer of protection is essential for preventing the 'rebound' pigmentation common in midlife [5, 7].
Can I use Vitamin C and Retinol together to treat melasma?
While both are beneficial, they should be used strategically. Vitamin C (L-ascorbic acid) acts as an antioxidant and tyrosinase inhibitor that is best used in the morning to neutralise free radicals. Retinoids (like Retinol or Tretinoin) are best used at night to stimulate cell turnover and disperse pigment. Using them together at the same time may cause irritation, which can lead to post-inflammatory hyperpigmentation in sensitive midlife skin. A 'sandwich' or staggered approach is usually recommended by dermatologists to ensure efficacy without compromising the skin barrier [1, 8].
References:
[1] Ogbechie-Godec OA, Elbuluk N. Melasma: an Up-to-Date Comprehensive Review. Dermatol Ther (Heidelb). 2017;7(3):305-318. doi:10.1007/s13555-017-0194-1
[2] Bala HR, et al. Oral Tranexamic Acid for the Treatment of Melasma: A Review. Dermatologic Surgery. 2018;44(6):814-825. doi:10.1097/DSS.0000000000001518
[3] Lee HC, et al. Oral tranexamic acid in the treatment of melasma: A retrospective analysis. Journal of the American Academy of Dermatology. 2016;75(2):385-392. doi:10.1016/j.jaad.2016.03.001
[4] Sarkar R, et al. Laser and Light Based Therapies in Melasma: A Review. Indian Journal of Dermatology. 2014;59(3):215-225. doi:10.4103/0019-5154.131378
[5] Dumas M, et al. The role of visible light in melasma and other skin hyperpigmentations. Journal of Cosmetic Dermatology. 2021;20(S1):12-17. doi:10.1111/jocd.14322
[6] Handel AC, et al. Melasma: a clinical and epidemiological review. Anais Brasileiros de Dermatologia. 2014;89(5):771-782. doi:10.1590/abd1806-4841.20143063
[7] Kohli I, et al. Impact of Long-Wavelength Ultraviolet A1 and Visible Light on Pigmentation. Journal of Investigative Dermatology. 2020;140(10):2085-2089. doi:10.1016/j.jid.2020.02.023
[8] Telang PS. Vitamin C in dermatology. Indian Dermatology Online Journal. 2013;4(2):143-146. doi:10.4103/2229-5178.110593
Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any new skincare regimen. Content reviewed by a biomedical scientist.
